Clinical Efficacy Of Relieving Yu And Resolving Phlegm In The Treatment Of Depression In The Recovery Period Of Ischemic Stroke With Phlegm And Qi Stagnation

Objective: To observe the clinical efficacy and safety of the treatment of mild to moderate depression in the recovery period of ischaemic stroke with phlegm and qi stagnation by Jieyuhuahuan Tang,so as to provide an objective basis for clinical application.Methods: Sixty patients with post-stroke depression(PSD)were randomly divided into two groups: 30 patients in the treatment group and 30 patients in the control group.The control group was given basic treatment for stroke,including antiplatelet,anti-alpine,antihypertensive and risk factor control;the control group was given sertraline hydrochloride on top of this basic treatment,and the observation group was given sertraline hydrochloride plus Chinese herbal medicine to relieve depression and dissolve phlegm soup,both groups were treated for 4 weeks.The depression scores,i.e.Hamilton depression scale(HAMD)scores,neurological function,i.e.National Institutes of Health Stroke Scale(NIHSS)scores and the ability to perform daily living,i.e.(Barthel,Bl)index,as well as the Chinese medicine syndrome score and other indicators that reflect the severity of the disease,to evaluate the effectiveness and safety of Jieyuhuahuan Tang.Results:1.Overall efficacy: The overall efficacy evaluation of this study for clinical efficacy observation was based on the efficacy of antidepressant symptoms.After statistical analysis,it was suggested that the total effective rate of the control group was 73.07% and the total effective rate of the treatment group was 100%.After rank sum test,Z=-5.144,P=0.00<0.05,the difference is statistically significant,indicating that the treatment group is better than the control group in the overall efficacy evaluation of depression.2.HAMD scores: After comparing the HAMD scores of the two groups of patients before treatment,it showed that P= 0.87>0.05,and the HAMD scores were comparable between the groups.After 4 weeks of treatment,the HAMD scores of patients in both groups decreased compared with those before treatment(P< 0.05),among which,the HAMD scores of the treatment group were lower than those of the control group(P< 0.05).3.NIHSS scores: After comparing the NIHSS scores of the two groups of patients before treatment,it showed that P= 0.88 > 0.05,and the NIHSS scores were comparable between the groups.After 4 weeks of treatment,the NIHSS scores of patients in both groups decreased compared with those before treatment(P< 0.05),among which,the NIHSS scores of the treatment group were lower than those of the control group(P< 0.05).4.BI scores: After comparing the BI scores of patients in both groups before treatment,P=0.64 >0.05,the BI scores between the groups were comparable.Both groups’ scores decreased compared with those before treatment(P <0.05),and the BI scores of the treatment group were lower than those of the control group(P < 0.05).5.Chinese medicine evidence points: After comparing the Chinese medicine evidence points of the two groups before treatment,P=0.64> 0.05,the Chinese medicine evidence points between the groups were comparable.After treatment,the points of both groups decreased compared with those before treatment(P<0.05),and the Chinese medicine evidence score of the treatment group was lower than that of the control group(P < 0.05).6.Safety analysis: No serious adverse reactions were observed during the trial.Patients in both groups had stable vital signs,no significant changes in blood routine,urine routine,stool routine,liver and kidney function,and electrocardiogram during the patient trial.Conclusion:1.The clinical efficacy of Jieyuhuahuan Phlegm Tang in treating depressed patients after ischaemic stroke with phlegm and qi stagnation is good,and it can improve the neurological function and enhance the ability of daily living of patients with PSD.2.The safety of Jieyuhuahuan Tang in treating PSD is good.